Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient

被引:0
|
作者
Franceschini, Gianluca [1 ]
Di Leone, Alba [1 ]
Sanchez, Alejandro Martin [1 ]
D'Archi, Sabatino [1 ]
Terribile, Daniela [1 ]
Magno, Stefano [1 ]
Scardina, Lorenzo [1 ]
Masetti, Riccardo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Dept Woman Child & Publ Hlth, IRCCS,Div Breast Surg, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Axillary treatment; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; AXILLARY DISSECTION; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Today, sentinel lymph node biopsy (SLNB) is considered the gold standard for axillary staging in early breast cancer patients with clinically negative lymph nodes (cNO). SLNB allows to determine the axillary lymph node status sparing the axillary dissection (AD) and its potential complications (seroma formation, loss of sensation, shoulder dysfunction and lymphedema) On the other hand, SLNB for nodal staging in breast cancer patients with clinically negative lymph nodes after neoadjuvant chemotherapy (ycN0) is a highly debated topic due to different reported success rates. In order to optimize oncological results, high identification rate (> 90%) and false negative rate as low as possible (< 10%) should always be obtained when performing SLNB after neoadjuvant chemotherapy. The success rates of SLNB after neoadjuvant chemotherapy (NAC) mainly depend on the clinical lymph node status pre-NAC. In patients with pre-NAC clinically negative nodes (cN0) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy should be performed because it is an accurate and safe procedure. In patients with pre-NAC clinically positive nodes (cN+) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy might be considered thanks to the high lymph nodal pathologic complete response rate; however, in this last setting, individual ability, technical skills and repetitive performance of specific tasks must always be followed to improve the identification rate and false negative rate. AD may be avoided only if sentinel lymph node is negative [ypN0(sn)J; instead, to date, patients with metastatic sentinel lymph node after neoadjuvant chemotherapy, even with only isolated tumor cells, fypN+(sn) including ypN0i+(sn) and ypN1mic(sn)J should always be treated with AD. However, NAC significantly increases the difficulties and complexity of axillary surgical management. A personalized multidisciplinary path in specialized breast centers should ensure an accurate clinical counselling and refined patient selection for SLNB post-NAC.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [41] Sentinel Lymph Node Biopsy in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Kolarik, D.
    Pecha, V.
    Sykorova, J.
    Kaus, K.
    Kozevnikova, R.
    Hovorkova, K.
    Hrabetova, P.
    Sottner, O.
    Trnkova, M.
    Kolarova, H.
    CANCER RESEARCH, 2010, 70
  • [42] Sentinel lymph node biopsy for patients with breast cancer treated with neoadjuvant chemotherapy
    Shimazu, K.
    Tamaki, Y.
    Taguchi, T.
    Noguchi, S.
    BREAST, 2009, 18 : S62 - S62
  • [43] Sentinel Node Biopsy in Breast Cancer: Before or after Neoadjuvant Chemotherapy?
    Mamounas, E. P.
    CANCER RESEARCH, 2012, 72
  • [44] Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with initial axillary node metastasis
    Testart, N.
    Rebollo-Aguirre, A. C.
    Sanchez-Sanchez, R.
    Aroui, T.
    Trivino-Ibanez, E. M.
    Garcia-Garcia, J.
    Menjon-Beltran, S.
    Llamas-Elvira, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S706 - S706
  • [45] Update - Sentinel lymph node biopsy for breast cancer
    Bold, RJ
    Schlieman, M
    Fahy, BN
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (05) : 347 - 357
  • [46] Outcomes of sentinel lymph node biopsy after neoadjuvant chemotherapy
    Rashad, S.
    Bulbul, A.
    Mino, E. A.
    Bautista, A.
    Mustafa, A.
    Chouial, S.
    Khorsand, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Experience of the sentinel lymph node biopsy after neoadjuvant chemotherapy
    Krivorotko, P.
    Zhiltsova, E.
    Dashayan, G.
    Trufanova, E.
    Tabagua, T.
    Ivanova, O.
    Bessonov, A.
    Komayachov, A.
    Nikolaev, K.
    Kanaev, S.
    Novikov, S.
    Krzivickiyi, P.
    Brayanceva, Z.
    Zernov, K.
    Paltuev, R.
    Emelyanov, A.
    Gigolaeva, L.
    Semiglazov, V.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S69 - S69
  • [48] Utility of the Sentinel Lymph Node Biopsy in Breast Cancer after Neoadjuvant Chemotherapy with Negative Axillary Lymph Nodes or Node Involvement
    Alvarez Mena, N.
    Sebastian Palacid, F.
    Turbay Eljach, P.
    Perez Lopez, B.
    Alonso Rodriguez, M.
    Gamazo Laherran, C.
    Sainz Esteban, A.
    Ruiz Gomez, M.
    Gonzalez Soto, M.
    Ruano Perez, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S506 - S506
  • [49] Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy
    Kim, Hyunhee
    Han, Jaihong
    Kim, Sun-Young
    Lee, Eun Sook
    Kang, Han-Sung
    Lee, Seeyoun
    Jung, So-Youn
    Lee, EunGyeong
    JOURNAL OF BREAST CANCER, 2021, 24 (06) : 531 - 541
  • [50] Prognostic Value of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Advanced Stage Breast Cancer
    Suta, T.
    Mutuleanu, M.
    Marian, S.
    Gherghe, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S489 - S489